Related Experiment Video
Updated: May 1, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast
1Division of Biomedical Cell Biology, Warwick Medical School, University of Warwick, Coventry, UK.
Background And Purpose:
The glucagon-like peptide 1 (GLP-1) receptor performs an important role in glycaemic control, stimulating the release of insulin. It is an attractive target for treating type 2 diabetes. Recently, several reports of adverse side effects following prolonged use of GLP-1 receptor therapies have emerged: most likely due to an incomplete understanding of signalling complexities.
Experimental Approach:
We describe the expression of the GLP-1 receptor in a panel of modified yeast strains that couple receptor activation to cell growth via single Gα/yeast chimeras. This assay enables the study of individual ligand-receptor G protein coupling preferences and the quantification of the effect of GLP-1 receptor ligands on G protein selectivity.
Key Results:
The GLP-1 receptor functionally coupled to the chimeras representing the human Gαs, Gαi and Gαq subunits. Calculation of the dissociation constant for a receptor antagonist, exendin-3 revealed no significant difference between the two systems. We obtained previously unobserved differences in G protein signalling bias for clinically relevant therapeutic agents, liraglutide and exenatide; the latter displaying significant bias for the Gαi pathway. We extended the use of the system to investigate small-molecule allosteric compounds and the closely related glucagon receptor.
Conclusions And Implications:
These results provide a better understanding of the molecular events involved in GLP-1 receptor pleiotropic signalling and establish the yeast platform as a robust tool to screen for more selective, efficacious compounds acting at this important class of receptors in the future.
Insights
A novel yeast assay reveals distinct G protein signaling preferences for GLP-1 receptor drugs, aiding the development of safer type 2 diabetes treatments.
Area of Science:
- Pharmacology
- Molecular Biology
- Biochemistry
Background:
- The glucagon-like peptide 1 (GLP-1) receptor is crucial for glycemic control and a key target for type 2 diabetes therapies.
- Adverse effects of current GLP-1 receptor agonists suggest a need for deeper understanding of their signaling pathways.
Purpose of the Study:
- To develop a novel yeast-based assay for studying GLP-1 receptor G protein coupling selectivity.
- To investigate signaling bias of GLP-1 receptor ligands and allosteric modulators.
Main Methods:
- Expression of the GLP-1 receptor in modified yeast strains coupled to G protein chimeras.
- Assessing receptor activation and G protein coupling preferences via cell growth.
- Quantifying ligand-receptor interactions and G protein selectivity.
Main Results:
- The GLP-1 receptor functionally coupled to human Gαs, Gαi, and Gαq chimeras.
- Identified distinct G protein signaling bias for liraglutide and exenatide, with exenatide favoring the Gαi pathway.
- Validated the system for evaluating allosteric compounds and the glucagon receptor.
Conclusions:
- The yeast platform provides a robust tool for dissecting GLP-1 receptor pleiotropic signaling.
- Enables screening for more selective and efficacious GLP-1 receptor agonists and modulators.
- Facilitates the development of improved therapeutics for type 2 diabetes with reduced side effects.
Related Concept Videos
Yeast Signaling
GPCRs Regulate Adenylyl Cylase Activity
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
G-protein Coupled Receptors
Amplifying Signals via Enzymatic Cascade

